Table 2. Clinical characteristics of the study patients according to the BRCA mutation status.
| Entire cohort | BRCA-positive patients | BRCA-negative patients | P | ||
|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | |||
| 99 (100) | 12 (12.1) | 87 (87.9) | |||
| Histology | 0.001 | ||||
| Serous carcinoma | 46 (46.5) | 12 (26.1) | 34 (73.9) | ||
| Endometrioid carcinoma | 24 (24.2) | 0 (0) | 24 (100) | ||
| Clear cell carcinoma | 29 (29.3) | 0 (0) | 29 (100) | ||
| Age, years | 0.069 | ||||
| Median | 52 | 56 | 52 | ||
| Range | 23−83 | 42−78 | 23−83 | ||
| Mean ± SD | 52.9 ± 11.1 | 58.4 ± 10.8 | 52.2 ± 11.0 | ||
| FIGO stage | 0.228 | ||||
| I, II | 42 (42.4)* | 3 (7.1)# | 39 (92.9)# | ||
| III, IV | 57 (57.6)* | 9 (15.8)§ | 48 (84.2)§ | ||
| Grade※ | 0.579 | ||||
| 1 | 5 (7.1)¶ | 0 (0) ǂ | 5 (100) ǂ | ||
| 2, 3 | 65 (92.9)¶ | 12 (18.5)ψ | 53 (81.5)ψ |
Patients with pathogenic BRCA1/2 mutations were considered as BRCA-positive, whereas the remaining patients were regarded as BRCA-negative. Comparisons between BRCA-positive and BRCA-negative patients were performed with Fisher's exact tests, χ2tests, or Student's t-tests, as appropriate.
※Clear cell carcinomas were not graded.
*Percentage calculated on the entire cohort (n = 99).
#Percentage calculated on patients with FIGO stages I and II (n = 42).
§ Percentage calculated on patients with FIGO stages III and IV (n = 57).
¶Percentage calculated on patients whose tumors were graded (n = 70).
ǂPercentage calculated on patients with grade 1 tumors (n = 5).
ψPercentage calculated on patients with grade 2–3 tumors (n = 65).